What is it about?

To compare the efficacy and safety of dapoxetine, paroxetine, and placebo for the oral pharmacotherapy of premature ejaculation.

Featured Image

Why is it important?

Premature ejaculation (PE) is the most prevalent male sexual dysfunction. Erectile dysfunction and decreased libido are less common. Data from the National Health and Social Life Survey have revealed a prevalence of 21% in men ages 18 to 59 in the United States. In general, the prevalence of PE is reported as being between 22% and 38% of adult male population


Unfortunately pharmaceutical companies largely affect some medical associations and societies and some physicians. Dapoxetine has been developed as an on-demand drug to treat premature ejaculation, but as of the end of 2005, has not been approved by the FDA as an oral drug for the treatment of premature ejaculation.

Dr Mohammad Reza Safarinejad
University of Medical Sceices

Read the Original

This page is a summary of: Comparison of Dapoxetine Versus Paroxetine in Patients With Premature Ejaculation, Clinical Neuropharmacology, September 2006, Wolters Kluwer Health,
DOI: 10.1097/01.wnf.0000228210.12194.46.
You can read the full text:




The following have contributed to this page